journal article·2022-10-03Open access

Meropenem/Vaborbactam and Cefiderocol as Combination or Monotherapy to Treat Multi-Drug Resistant Gram-Negative Infections: A Regional Cross-Sectional Survey from Piedmont Infectious Disease Unit Network (PIDUN)

Tommaso Lupia, Silvia Corcione, Nour Shbaklo, Giorgia Montrucchio, Ilaria De Benedetto, Valentina Fornari, Roberta Bosio, Barbara Rizzello, Simone Mornese Pinna, Luca Brazzi, Francesco Giuseppe De Rosa

Abstract

Meropenem/vaborbactam (MV) and cefiderocol were recently approved by the Food and Drug Administration and European Medicines Agency and are among the most promising antibacterial in treatment regimens against multi-drug resistant (MDR) gram-negative bacilli. A survey with close-ended questions was proposed to infectious disease (ID) and intensive care unit (ICU) physicians of Piedmont and Valle d’Aosta Region’s hospitals. The aim was to collect data about habits and prescriptions of cefiderocol and MV. Twenty-three physicians (11 ID specialists and 12 anesthesiologists) in 13 Italian hospitals took part in the survey. Both cefiderocol and MV were mostly used as target therapy after a previous treatment failure and after ID specialist consult. The most frequent MDR pathogen in hospitals was Klebsiella pneumoniae carbapenemase-producing bacteria (KPC), followed by P. aeruginosa and A. baumannii. MDRs were more frequently isolated in ICU. In conclusion, cefiderocol was used in empiric regimens when A. baumannii was suspected, while MV was more used in suspect of KPC. MV and cefiderocol can be the first option in empiric treatment for critically ill patients in settings with high risk of MDR. The treatment should then be followed by rapid de-escalation when microbiological results are available.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Antibiotics Pharmacokinetics and Efficacy · Antibiotic Resistance in Bacteria · Pneumonia and Respiratory Infections

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Unit of Infectious Diseases, Cardinal Massaia, 14100 Asti, Italy

Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy

School of Medicine, Tufts University, Boston, MA 02111, USA

Department of Surgical Sciences, University of Turin, 10126 Turin, Italy

Department of Anaesthesia, Critical Care and Emergency, Città Della Salute e Della Scienza Hospital, Corso Dogliotti 14, 10126 Turin, Italy

References (33)

Show source-provided references
1. Continuous Evolution: Perspective on the Epidemiology of Carbapenemase Resistance Among Enterobacterales and Other Gram-Negative Bacteria10.1007/s40121-020-00395-2 ↗
2. Principe, L., Lupia, T., Andriani, L., Campanile, F., Carcione, D., Corcione, S., De Rosa, F.G., Luzzati, R., Stroffolini, G., and Steyde, M. (2022). Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians. Pharmaceuticals, 15.10.3390/ph15040463 ↗
3. Multidrug-resistant Gram-negative bacterial infections: Are you ready for the challenge?10.2174/15748847113089990062 ↗
4. Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective10.3389/fmed.2021.617378 ↗
5. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship10.1007/s40265-019-01112-1 ↗
6. (2022, June 05). Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibacterial-drug.
7. (2022, June 05). Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibacterial-drug-treat-complicated-urinary-tract-infections-part-ongoing-efforts.
8. (2022, June 05). Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/vaborem#authorisation-details-section.
9. (2022, June 05). Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/fetcroja.
10. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial10.1001/jama.2018.0438 ↗
11. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial10.1007/s40121-018-0214-1 ↗
12. Cefiderocol versus High-Dose, Extended-Infusion Meropenem for the Treatment of Gram-Negative Nosocomial Pneumonia (APEKS-NP): A Randomised, Double-Blind, Phase 3, Non-Inferiority Trial10.1016/S1473-3099(20)30731-3 ↗
13. Efficacy and Safety of Cefiderocol or Best Available Therapy for the Treatment of Serious Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria (CREDIBLE-CR): A Randomised, Open-Label, Multicentre, Pathogen-Focused, Descriptive, Phase 3 Trial10.1016/S1473-3099(20)30796-9 ↗
14. Perceived differences between intensivists and infectious diseases consultants facing antimicrobial resistance: A global cross-sectional survey10.1007/s10096-019-03530-1 ↗
15. Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections10.1007/s40265-021-01580-4 ↗
16. Babidhan, R., Lewis, A., Atkins, C., Jozefczyk, N.J., Nemecek, B.D., Montepara, C.A., Gionfriddo, M.R., Zimmerman, D.E., Covvey, J.R., and Guarascio, A.J. (Pharmacotherapy, 2022). Safety and efficacy of cefiderocol for off-label treatment indications: A systematic review, Pharmacotherapy, Epub ahead of print.10.1002/phar.2704 ↗
17. New evidence in severe pneumonia: Meropenem-vaborbactam10.37201/req/s01.10.2022 ↗
18. Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: A multicentre study10.1093/jacamr/dlac022 ↗
19. Role of the infectious diseases specialist consultant on the appropriateness of antimicrobial therapy prescription in an intensive care unit10.1016/j.ajic.2007.06.009 ↗
20. Influence of an infectious diseases specialist on ICU multidisciplinary rounds
21. (2022, July 08). Available online: https://www.aifa.gov.it/en/web/guest/farmaci-carenti.
22. Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: A contemporary, multidisciplinary ESGCIP perspective10.1080/14787210.2022.2063838 ↗
23. (2022, July 08). Available online: https://microbeonline.com/e-test-epsilometer-test-principle-purpose-procedure-results-and-interpretations/.
24. (2022, July 08). Available online: https://www.eucast.org/ast_of_bacteria/mic_determination/.
25. (2022, July 08). Available online: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/2022_manuals/Reading_guide_BMD_v_4.0_2022.pdf.
26. The Impact of Fast Microbiology in Intensive Care Units in the Era of Antibiotic Resistance: An Observational Retrospective Study10.1007/s00284-022-02773-0 ↗
27. Gorham, J., Taccone, F.S., and Hites, M. (2022). Drug Regimens of Novel Antibiotics in Critically Ill Patients with Varying Renal Functions: A Rapid Review. Antibiotics, 11.10.3390/antibiotics11050546 ↗
28. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era10.1007/s10096-022-04408-5 ↗
29. Shbaklo, N., Corcione, S., Vicentini, C., Giordano, S., Fiorentino, D., Bianco, G., Cattel, F., Cavallo, R., Zotti, C.M., and De Rosa, F.G. (2022). An Observational Study of MDR Hospital-Acquired Infections and Antibiotic Use during COVID-19 Pandemic: A Call for Antimicrobial Stewardship Programs. Antibiotics, 11.10.3390/antibiotics11050695 ↗
30. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)10.1016/j.cmi.2021.11.025 ↗
31. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant EnterobacteriaceaeInfections10.1128/AAC.02313-19 ↗
32. Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: A multicentre cohort study10.1093/jacamr/dlab174 ↗
33. Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii10.1128/aac.02142-21 ↗